Bailey Pemberton
4 min read
Medicover has rewarded long term holders with a strong share price run, which naturally raises a simple question for anyone looking at the stock today. Is the current price at SEK 276 still aligned with what the healthcare group is earning?
-
Over the past 3 years Medicover has delivered a total return of 130.7%, so a lot of optimism is already embedded in the story and this puts more weight on whether the earnings base can justify that journey.
-
The group’s model of combining healthcare services with diagnostics can support relatively steady revenue and profit streams, which matters for how much investors are prepared to pay for each krona of earnings.
-
Your read on Medicover is one view; the desks covering it have another. See what analysts think Medicover’s shares could be worth.
The stock’s next move may depend on whether Medicover’s current earnings are strong and reliable enough to underpin the price investors are paying today.
If you are weighing Medicover against other opportunities that also hinge on earnings strength, it can help to run a focused stock screen built around 193 high quality undervalued stocks.
Is Medicover Getting Expensive on Earnings?
The P/E ratio suits Medicover because investors are clearly focused on what each krona of profit is worth. At SEK 276, the stock trades on about 44.4x earnings, which is far above the broader healthcare sector average of roughly 18.8x. That indicates buyers are willing to pay a premium for the group’s earnings stream.
Compared with more direct peers, Medicover’s P/E multiple is close to the peer pack at around 44.7x, so the premium appears to reflect how the whole specialist group is priced rather than Medicover alone. A tailored model that looks at Medicover’s own growth profile, profitability and risk points to a lower P/E as a more grounded anchor, which means the current valuation screens as overvalued on this lens. Explore the numbers behind Medicover’s P/E valuation.
The Medicover Narrative: What Would Justify Today’s Price?
Narratives pick up where the P/E puzzle leaves off, by spelling out which paths for Medicover’s future growth, margins and earnings would need to play out for the equity to be worth meaningfully more or less than today’s price. They sit on Simply Wall St’s Community page. Rather than relying on a single ratio or model point estimate, each narrative lays out its own assumptions so you can compare those building blocks with Medicover’s reported results over time.
Community views on Medicover split between those who see extra upside from the Europe focused reset and others who think most of that story is already reflected in the price.
